Spots Global Cancer Trial Database for bone marrow aspiration and biopsy

Every month we try and update this database with for bone marrow aspiration and biopsy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant	NCT05799079	Recurrent Acute...	Venetoclax Decitabine Cedazuridine Bone Marrow Asp... Biospecimen Col...	18 Years -	Vanderbilt-Ingram Cancer Center
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia	NCT05453500	B Acute Lymphob...	Bone Marrow Asp... Cyclophosphamid... Doxorubicin Etoposide Prednisone Rituximab Tafasitamab Vincristine	18 Years -	University of Washington
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia	NCT05549661	Recurrent Chron... Refractory Chro...	Biospecimen Col... Bone Marrow Asp... Onvansertib Ultrasound Imag...	18 Years -	Mayo Clinic
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia	NCT02981628	Recurrent B Acu... Recurrent B Lym... Refractory B Ac... Refractory B Ly...	Asparaginase Er... Biospecimen Col... Bone Marrow Asp... Calaspargase Pe... Cyclophosphamid... Cytarabine Diagnostic Imag... Inotuzumab Ozog... Leucovorin Calc... Lumbar Puncture Methotrexate Pegaspargase Vincristine	1 Year - 21 Years	Children's Oncology Group
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial	NCT05497804	ISS Stage III P... Plasma Cell Mye...	Bone Marrow Asp... Carfilzomib Computed Tomogr... Daratumumab Dexamethasone Lenalidomide Magnetic Resona... Positron Emissi...	18 Years - 80 Years	Mayo Clinic
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)	NCT03970096	Acute Leukemia Acute Lymphobla... Acute Myeloid L... Myelodysplastic...	Total-Body Irra... Thiotepa Fludarabine Tacrolimus Allogeneic CD34... Methotrexate Cyclophosphamid... Peripheral Bloo... Cyclosporine Sirolimus Busulfan Bone Marrow Asp... Echocardiograph... Multigated Acqu... Biospecimen Col...	1 Year - 60 Years	Fred Hutchinson Cancer Center
Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis	NCT02805868	Myelofibrosis Polycythemia Ve... Primary Myelofi... Thrombocytopeni...	Bone Marrow Asp... Laboratory Biom... Siltuximab	18 Years -	Northwestern University
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia	NCT06399640	Relapsed Myelod... Refractory Myel... Acute Myeloid L... Recurrent Acute... Refractory Acut...	Eltanexor Venetoclax Bone Marrow Asp... Biospecimen Col...	18 Years -	Vanderbilt-Ingram Cancer Center
Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients	NCT04817241	Acute Myeloid L...	Biospecimen Col... Bone Marrow Asp... Cytarabine Daunorubicin Decitabine and ... Venetoclax	18 Years - 65 Years	National Cancer Institute (NCI)
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma	NCT04609046	Primary Diffuse...	Bone Marrow Asp... Computed Tomogr... Echocardiograph... Lenalidomide Lumbar Puncture Magnetic Resona... Methotrexate Nivolumab Positron Emissi... Rituximab Ultrasound Imag...	18 Years -	National Cancer Institute (NCI)
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome	NCT03670966	Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Recurrent Acute... Refractory Acut... Refractory Acut... Recurrent Mixed... Refractory Mixe... Hematopoietic a...	Astatine At 211... Cyclophosphamid... Total-Body Irra... Peripheral Bloo... Bone Marrow Tra... Mycophenolate M... Recombinant Gra... Fludarabine Pho... Tacrolimus Bone Marrow Asp... Biospecimen Col...	18 Years - 75 Years	Fred Hutchinson Cancer Center
Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	NCT02971397	Acute Myeloid L...	Bone Marrow Asp... Cytarabine Daunorubicin Hy... Laboratory Biom...	18 Years -	Wake Forest University Health Sciences
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia	NCT04872790	B Acute Lymphob... B Acute Lymphob... Mixed Phenotype... Recurrent B Acu... Recurrent Mixed...	Dasatinib Methotrexate Prednisone Rituximab Venetoclax Blinatumomab Bone Marrow Asp... Lumbar Puncture Biospecimen Col...	18 Years -	OHSU Knight Cancer Institute
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma	NCT06249191	Diffuse Large B... High Grade B-Ce...	Biopsy Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Cyclophosphamid... Doxorubicin Echocardiograph... Etoposide Magnetic Resona... Mosunetuzumab Multigated Acqu... Positron Emissi... Prednisone Vincristine	18 Years - 75 Years	OHSU Knight Cancer Institute
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial	NCT05554328	Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Biopsy Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Echocardiograph... Multigated Acqu... Olaparib Selumetinib Sul...	18 Years -	National Cancer Institute (NCI)
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis	NCT04847453	AL Amyloidosis	Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Dexamethasone Ixazomib Citrat... Magnetic Resona... Positron Emissi... Transabdominal ... Venetoclax X-Ray Imaging	18 Years -	National Cancer Institute (NCI)
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat	NCT05320380	Recurrent Acute... Recurrent B Acu... Recurrent Mixed... Recurrent T Acu... Refractory Acut... Refractory B Ac... Refractory Mixe... Refractory T Ac...	Anti-CD123 ADC ... Bone Marrow Asp... Cytarabine Fludarabine Pho... Hydrocortisone ... Liposome-encaps... Methotrexate Prednisolone	12 Months - 22 Years	Children's Oncology Group
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma	NCT03031730	Plasmacytoma Recurrent Multi... Refractory Mult...	Biospecimen Col... Bone Marrow Asp... Carfilzomib Dexamethasone Dexamethasone S... Echocardiograph... Lenalidomide Navtemadlin	18 Years -	National Cancer Institute (NCI)
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial	NCT04284774	Malignant Solid... Recurrent Adren... Recurrent Ectom... Recurrent Epend... Recurrent Ewing... Recurrent Hepat... Recurrent Kidne... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Melan... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Rhabd... Recurrent Rhabd... Recurrent Rhabd... Recurrent Soft ... Recurrent Thyro... Recurrent WHO G... Refractory Adre... Refractory Epen... Refractory Ewin... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Mela... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Rhab... Refractory Rhab... Refractory Rhab... Refractory Soft... Refractory Thyr... Refractory WHO ...	Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Magnetic Resona... Positron Emissi... Radionuclide Im... Tipifarnib	12 Months - 21 Years	National Cancer Institute (NCI)
CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission	NCT05707273	B Acute Lymphob...	Autologous Anti... Biospecimen Col... Bone Marrow Asp... Cyclophosphamid... Fludarabine Leukapheresis Questionnaire A...	55 Years -	City of Hope Medical Center
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)	NCT03970096	Acute Leukemia Acute Lymphobla... Acute Myeloid L... Myelodysplastic...	Total-Body Irra... Thiotepa Fludarabine Tacrolimus Allogeneic CD34... Methotrexate Cyclophosphamid... Peripheral Bloo... Cyclosporine Sirolimus Busulfan Bone Marrow Asp... Echocardiograph... Multigated Acqu... Biospecimen Col...	1 Year - 60 Years	Fred Hutchinson Cancer Center
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia	NCT03150693	B Acute Lymphob...	Allopurinol Cytarabine Daunorubicin Hy... Vincristine Sul... Dexamethasone Pegylated L-Asp... Methotrexate Bone Marrow Asp... Cyclophosphamid... Mercaptopurine Rituximab Doxorubicin Thioguanine Inotuzumab Ozog... Laboratory Biom...	18 Years - 39 Years	Alliance for Clinical Trials in Oncology
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma	NCT04609046	Primary Diffuse...	Bone Marrow Asp... Computed Tomogr... Echocardiograph... Lenalidomide Lumbar Puncture Magnetic Resona... Methotrexate Nivolumab Positron Emissi... Rituximab Ultrasound Imag...	18 Years -	National Cancer Institute (NCI)
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial	NCT05554328	Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Biopsy Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Echocardiograph... Multigated Acqu... Olaparib Selumetinib Sul...	18 Years -	National Cancer Institute (NCI)
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma	NCT06249191	Diffuse Large B... High Grade B-Ce...	Biopsy Biospecimen Col... Bone Marrow Asp... Computed Tomogr... Cyclophosphamid... Doxorubicin Echocardiograph... Etoposide Magnetic Resona... Mosunetuzumab Multigated Acqu... Positron Emissi... Prednisone Vincristine	18 Years - 75 Years	OHSU Knight Cancer Institute
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults	NCT04530565	B Acute Lymphob...	Biospecimen Col... Blinatumomab Bone Marrow Asp... Cyclophosphamid... Cytarabine Dasatinib Dexamethasone Doxorubicin Hyd... Echocardiograph... Electrocardiogr... Lumbar Puncture Mesna Methotrexate Multigated Acqu... Ponatinib Hydro... Prednisone Vincristine Sul...	18 Years - 75 Years	National Cancer Institute (NCI)
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia	NCT06399640	Relapsed Myelod... Refractory Myel... Acute Myeloid L... Recurrent Acute... Refractory Acut...	Eltanexor Venetoclax Bone Marrow Asp... Biospecimen Col...	18 Years -	Vanderbilt-Ingram Cancer Center
Palbociclib or Tazemetostat in Combination With CPX-351 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia	NCT05627232	Recurrent Acute... Refractory Acut...	Tazemetostat Liposome-encaps... Bone Marrow Asp... Biospecimen Col... Palbociclib	18 Years -	Thomas Jefferson University
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat	NCT05320380	Recurrent Acute... Recurrent B Acu... Recurrent Mixed... Recurrent T Acu... Refractory Acut... Refractory B Ac... Refractory Mixe... Refractory T Ac...	Anti-CD123 ADC ... Bone Marrow Asp... Cytarabine Fludarabine Pho... Hydrocortisone ... Liposome-encaps... Methotrexate Prednisolone	12 Months - 22 Years	Children's Oncology Group
Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study	NCT05641831	Clonal Cytopeni...	Biospecimen Col... Bone Marrow Asp... Canakinumab Chest Radiograp... Echocardiograph... Placebo Adminis... Quality-of-Life...	18 Years -	Ohio State University Comprehensive Cancer Center
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia	NCT03190915	Juvenile Myelom... Neurofibromatos...	Bone Marrow Asp... Trametinib	1 Month - 21 Years	National Cancer Institute (NCI)
Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes	NCT04802161	Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Myeloproliferat...	Biospecimen Col... Bone Marrow Asp... Liposome-encaps... Pomalidomide	18 Years - 75 Years	National Cancer Institute (NCI)
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia	NCT04872790	B Acute Lymphob... B Acute Lymphob... Mixed Phenotype... Recurrent B Acu... Recurrent Mixed...	Dasatinib Methotrexate Prednisone Rituximab Venetoclax Blinatumomab Bone Marrow Asp... Lumbar Puncture Biospecimen Col...	18 Years -	OHSU Knight Cancer Institute
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)	NCT03970096	Acute Leukemia Acute Lymphobla... Acute Myeloid L... Myelodysplastic...	Total-Body Irra... Thiotepa Fludarabine Tacrolimus Allogeneic CD34... Methotrexate Cyclophosphamid... Peripheral Bloo... Cyclosporine Sirolimus Busulfan Bone Marrow Asp... Echocardiograph... Multigated Acqu... Biospecimen Col...	1 Year - 60 Years	Fred Hutchinson Cancer Center
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma	NCT03031730	Plasmacytoma Recurrent Multi... Refractory Mult...	Biospecimen Col... Bone Marrow Asp... Carfilzomib Dexamethasone Dexamethasone S... Echocardiograph... Lenalidomide Navtemadlin	18 Years -	National Cancer Institute (NCI)
Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis	NCT04384692	Primary Myelofi... Secondary Myelo...	Allogeneic Hema... Busulfan Cyclophosphamid... Fludarabine Melphalan Methotrexate Mycophenolate M... Ruxolitinib Tacrolimus Total-Body Irra... Computed Tomogr... Echocardiograph... Bone Marrow Asp... Magnetic Resona... Ultrasound Imag...	18 Years -	Fred Hutchinson Cancer Center
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma	NCT04609046	Primary Diffuse...	Bone Marrow Asp... Computed Tomogr... Echocardiograph... Lenalidomide Lumbar Puncture Magnetic Resona... Methotrexate Nivolumab Positron Emissi... Rituximab Ultrasound Imag...	18 Years -	National Cancer Institute (NCI)
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	NCT03155620	Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Histiocytic Sar... Juvenile Xantho... Langerhans Cell... Malignant Gliom... Recurrent Child... Recurrent Epend... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Prima... Recurrent Rhabd... Recurrent Soft ... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Prim... Refractory Rhab... Refractory Rhab... Rhabdoid Tumor Stage III Osteo... Stage III Soft ... Stage IV Osteos... Stage IV Soft T... Stage IVA Osteo... Stage IVB Osteo... Wilms Tumor	Biopsy Biospecimen Col... Bone Marrow Asp... Bone Scan Computed Tomogr... Ensartinib Erdafitinib Laboratory Biom... Larotrectinib S... Magnetic Resona... Mutation Carrie... Olaparib Palbociclib Pharmacological... Positron Emissi... Radionuclide Im... Samotolisib Selpercatinib Selumetinib Sul... Tazemetostat Tipifarnib Ulixertinib Vemurafenib X-Ray Imaging	12 Months - 21 Years	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: